Tranexamic Acid for Ultra-Early Treatment of Intracerebral Hemorrhage

Tranexamic acid was not useful for preventing hematoma growth when used within 2 hours of stroke onset.

No definitive pharmacologic therapy exists for early treatment in intracerebral hemorrhage (ICH). One option being evaluated is an antifibrinolytic agent such as tranexamic acid (TXA). Previous studies have confirmed TXA's safety in this setting, but data on efficacy have been mixed. In this multinational clinical trial, researchers randomized patients with ICH who could be treated within 2 hours of stroke detection to receive either intravenous TXA (1 g over 10 minutes followed by 1 g over 8 hours) or placebo. Patients were excluded if they had a Glasgow Coma Scale score <8 or a hematoma volume >70 mL. The primary outcome was hematoma growth, defined as at least 33% relative growth or 6 mL of absolute growth on computed tomography at 24 ho…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Tranexamic Acid for Ultra-Early Treatment of Intracerebral Hemorrhage

Topics

Reviewing Author